Revance Therapeutics logo

Revance TherapeuticsNASDAQ: RVNC

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

06 February 2014

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$403.87 M
-87%vs. 3y high
62%vs. sector
-vs. 3y high
-vs. sector
-101%vs. 3y high
8%vs. sector
-93%vs. 3y high
32%vs. sector

Price

after hours | Wed, 20 Nov 2024 00:58:50 GMT
$3.85-$0.23(-5.64%)

Dividend

No data over the past 3 years
$59.88 M$71.73 M
$59.88 M-$38.12 M

Analysts recommendations

Institutional Ownership

RVNC Latest News

Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about Securities Fraud Investigation - RVNC
accesswire.com11 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
prnewswire.com10 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Levi & Korsinsky Reminds Shareholders of an Investigation into Revance Therapeutics, Inc. (RVNC) Regarding Potential Securities Fraud Allegations
accesswire.com08 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
accesswire.com08 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates
zacks.com07 November 2024 Sentiment: NEUTRAL

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.74 per share a year ago.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Revance Therapeutics, Inc. (RVNC)
accesswire.com07 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
accesswire.com06 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
accesswire.com04 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
prnewswire.com02 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Revance Therapeutics, Inc. (RVNC) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
accesswire.com01 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

  • 1(current)
  • 2
  • 3

What type of business is Revance Therapeutics?

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

What sector is Revance Therapeutics in?

Revance Therapeutics is in the Healthcare sector

What industry is Revance Therapeutics in?

Revance Therapeutics is in the Biotechnology industry

What country is Revance Therapeutics from?

Revance Therapeutics is headquartered in United States

When did Revance Therapeutics go public?

Revance Therapeutics initial public offering (IPO) was on 06 February 2014

What is Revance Therapeutics website?

https://www.revance.com

Is Revance Therapeutics in the S&P 500?

No, Revance Therapeutics is not included in the S&P 500 index

Is Revance Therapeutics in the NASDAQ 100?

No, Revance Therapeutics is not included in the NASDAQ 100 index

Is Revance Therapeutics in the Dow Jones?

No, Revance Therapeutics is not included in the Dow Jones index

When was Revance Therapeutics the previous earnings report?

No data

When does Revance Therapeutics earnings report?

The next expected earnings date for Revance Therapeutics is 28 February 2025